
Shares of Apellis Pharmaceuticals APLS.O rise 7.7% to $28.01 premarket, set to snap six-day losing streak
Drugmaker's Q4 revenue of $212.5 mln beats Wall Street estimates of $198.4 mln - LSEG
Q4 net loss $36.4 mln, narrower than $88.6 mln a year ago
APLS fell 46.7% in 2024